Opus Genetics (STU:R3X1) Scaled Net Operating Assets : -0.05 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Opus Genetics's operating assets for the quarter that ended in Sep. 2024 was €3.38 Mil. Opus Genetics's operating liabilities for the quarter that ended in Sep. 2024 was €5.49 Mil. Opus Genetics's Total Assets for the quarter that ended in Jun. 2024 was €41.65 Mil. Therefore, Opus Genetics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -0.05.

Opus Genetics Scaled Net Operating Assets Historical Data

The historical data trend for Opus Genetics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Scaled Net Operating Assets Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-1.92

-15.29

-0.12

0.15

-0.01

Opus Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.19	-0.01	-0.02	-0.02	-0.05

Competitive Comparison of Opus Genetics's Scaled Net Operating Assets

For the Biotechnology subindustry, Opus Genetics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Scaled Net Operating Assets falls into.

Opus Genetics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Opus Genetics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(3.147	-	3.707)	/	46.248
=	-0.01

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	49.47	-	46.323
=	3.147

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	3.707	-	0	-	0
=	3.707

Opus Genetics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(3.382	-	5.486)	/	41.651
=	-0.05

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	36.39	-	33.008
=	3.382

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5.486	-	0	-	0
=	5.486

Opus Genetics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

IRD:USA R3X1:Germany

Address

37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines